Neuphoria Therapeutics Inc
Officers & Directors
Spyridon “Spyros” Papapetropoulos, M.D., has served as President and Chief Executive Officer since January 5, 2023. He is a biopharmaceutical executive and neuroscientist/neurologist with 25 years of experience focused on central nervous system disorders. Previously, he was Chief Medical Officer at Vigil Neuroscience Inc. from 2020 and held senior positions at Acadia Pharmaceuticals Inc., SwanBio Therapeutics, Cavion, Biogen Inc., Allergan plc, Pfizer Inc., and Teva Pharmaceuticals Inc. He holds an MD and PhD from the University of Patras and was faculty at the University of Miami. Tim Cunningham has served as Chief Financial Officer since July 1, 2023, through a consulting agreement with Danforth Advisors LLC. He has been a CFO Consultant at Danforth since 2020 and was previously CFO at Organogenesis (NASDAQ:ORGO). He holds an MBA from Boston University, a BS in Accounting from Boston College, and is a CPA in Florida.
News about Neuphoria Therapeutics Inc Key Personnel |
Neuphoria Therapeutics Reports Strong First Quarter 2025 Business Updates Amid Promising Stock PerformanceBURLINGTON, Mass. May 20, 2025 – Neuphoria Therapeutics Inc. (Nasdaq: NEUP), a forward-thinking, clinical-stage biotechnology firm specializing in innovative treatments for neuropsychiatric disorders, has released significant business updates for the first quarter of 2025. This announcement arrives at a time when the company’s stock is demonstrating resilience and growth, trading 4.1% above its 52-week average.Over the last quarter, Neuphoria has made notable strides in both research and corporate strategy, showcasing its commitment to addressing critical gaps in the treatment of neuropsychiatric con...
|
|
